JP2024518788A5 - - Google Patents

Info

Publication number
JP2024518788A5
JP2024518788A5 JP2023569684A JP2023569684A JP2024518788A5 JP 2024518788 A5 JP2024518788 A5 JP 2024518788A5 JP 2023569684 A JP2023569684 A JP 2023569684A JP 2023569684 A JP2023569684 A JP 2023569684A JP 2024518788 A5 JP2024518788 A5 JP 2024518788A5
Authority
JP
Japan
Prior art keywords
composition according
oligonucleotide
bases
base
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028450 external-priority patent/WO2022240795A1/en
Publication of JP2024518788A publication Critical patent/JP2024518788A/ja
Publication of JP2024518788A5 publication Critical patent/JP2024518788A5/ja
Pending legal-status Critical Current

Links

JP2023569684A 2021-05-10 2022-05-10 ナトリウムチャネル1.6を標的とする組成物 Pending JP2024518788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186342P 2021-05-10 2021-05-10
US63/186,342 2021-05-10
PCT/US2022/028450 WO2022240795A1 (en) 2021-05-10 2022-05-10 Compositions targeting sodium channel 1.6

Publications (2)

Publication Number Publication Date
JP2024518788A JP2024518788A (ja) 2024-05-02
JP2024518788A5 true JP2024518788A5 (cg-RX-API-DMAC10.html) 2025-05-19

Family

ID=84028798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569684A Pending JP2024518788A (ja) 2021-05-10 2022-05-10 ナトリウムチャネル1.6を標的とする組成物

Country Status (5)

Country Link
US (1) US20220370487A1 (cg-RX-API-DMAC10.html)
EP (1) EP4337772A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024518788A (cg-RX-API-DMAC10.html)
CA (1) CA3219942A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022240795A1 (cg-RX-API-DMAC10.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112633A1 (en) * 2003-09-17 2005-05-26 Armour Christopher D. Alternatively spliced isoforms of sodium channel, voltage gated, type VIII, alpha (SCN8A)
EP1799859B1 (en) * 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP2410053B2 (en) * 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
WO2015187988A1 (en) * 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
GB2547586A (en) * 2014-08-20 2017-08-23 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
EP3183347A4 (en) * 2015-10-17 2018-04-18 Lifesplice Pharma LLC Splice modulating oligonucleotides and methods of use thereof
LT3700570T (lt) * 2017-10-23 2025-04-10 Stoke Therapeutics, Inc. Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui
IL300258A (en) * 2020-08-07 2023-03-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating SCN2A

Similar Documents

Publication Publication Date Title
JP7830340B2 (ja) PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法
JP2021533762A5 (cg-RX-API-DMAC10.html)
JP2016522674A5 (cg-RX-API-DMAC10.html)
JP2018516091A5 (cg-RX-API-DMAC10.html)
JP2016521556A5 (cg-RX-API-DMAC10.html)
JP2015523853A5 (cg-RX-API-DMAC10.html)
CN105008533A (zh) 嵌合单链反义多核苷酸和双链反义试剂
IL247600B (en) Preparations for the modulation of ataxin 2 expression
CN111918968B (zh) Micro-RNA 22的抑制剂
JP2009535039A5 (cg-RX-API-DMAC10.html)
KR20200024793A (ko) 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
US20250163419A1 (en) Therapeutic compositions for treating pain via multiple targets
CA2957618A1 (en) Inhibitors of myh7b and uses thereof
WO2024137543A1 (en) Advanced rna targeting (arnatar)
US20250250570A1 (en) Translation enhancing nucleic acid compounds: aso coupled translation – upregulation 1 (act-up1) and uses thereof
JP2024506709A5 (cg-RX-API-DMAC10.html)
CA3211396A1 (en) Ube3a antisense therapeutics
JP2023542889A5 (cg-RX-API-DMAC10.html)
NZ554277A (en) Antisense modulation of integrin alpha 4 expression
CN116670276A (zh) 用于通过多个靶标治疗疼痛的治疗组合物
KR20260061212A (ko) 인히빈 서브유닛 베타 E (INHBE)의 발현을 억제하기 위한 RNAi 작용제, 그의 제약 조성물, 및 사용 방법
US20240209377A1 (en) Therapeutic compositions for treating pain via multiple targets
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法
US20250277222A1 (en) Therapeutic compositions for treating pain via multiple targets
US12163132B2 (en) Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19